Press release Full year and fourth quarter 2020 - GSK

* Reported AER and CER growth rates for 2020 include five months’ results of the former Pfizer consumer healthcare business in 2019. Pro-forma CER growth rates are calculated as if the equivalent seven months of Pfizer consumer healthcare business results, as reported by Pfizer, were included in the comparative period of 2019.

  Pfizer

Annual Report 2019 - GSK

Trust We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. Our values and expectations Our values – patient focus, transparency, respect and integrity. Our expectations – courage, accountability, development and teamwork.

  Trust, Annual, Report, Annual report, Affordable

Annual Report 2020 - GSK

framework, we invest in our business to provide shareholder returns. In 2020 we paid a dividend of 80p per share and delivered £5.4 billion of free cash flow. We make a positive contribution to the communities in . which we operate. We employ over 94,000 people across 96 countries and work directly with 36,000 suppliers.

  Annual, Report, Return, 2200, Shareholders, 2002 annual report, Shareholder returns

Financial statements - GSK

The Group financial statements for the year ended . 31 December 2020, comprising principal statements and supporting notes, are set out in the ‘Financial statements’ on pages 154 to 237 of this report. The parent company financial statements for the year ended 31 December 2020, comprising the balance sheet and the statement of changes in

  Testament, Financial, Financial statements

Emma Walmsley, CEO - gsk.com

Agenda 2 Q2 2018 progress (15 mins) Emma Walmsley, Chief Executive Officer Q2 2018 financial results (15 mins) Simon Dingemans, Chief Financial Officer

  Mame

Audit & Risk Committee Terms of Reference - Home | GSK

Audit & Risk Committee – Terms of Reference 2 3. Each of the members of the Committee shall be independent Non-Executive Directors, as determined by the Board of the Company, in accordance with the provisions of the UK Corporate

  Terms, Risks, Reference, Committees, Audit, Terms of reference audit amp risk committee

Press release Third quarter 2021

Issued: Wednesday, 27 October 2021, London, U.K. 3 Operating performance – Q3 2021 Turnover Q3 2021 £m Growth £% Growth CER% Pharmaceuticals 4,397 5 10 Vaccines 2,174 7 13 Consumer Healthcare 2,506 3 8 Group turnover 9,077 5 10 Group turnover was £9,077 million in the quarter, up 5% AER, 10% CER.

  October, 27 october

Q3 2021 results

Progressing towards demerger at pace. 8. 1. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. 2021-26 CAGR is for the 5 …

ESG Performance Summary 2020 - GSK

Employee turnover Overall turnover (%) – – 12.5 15.7 Calculated as the number of permanent employees that left GSK in 2020 for any reason divided by the average 2020 permanent headcount. Turnover of voluntary leavers (%) – – 6.7 5.6 Calculated as the number of permanent employees that voluntarily left GSK in 2020

  Performance, Employee, Summary, 2200, Turnover, Employee turnover, Esg performance summary 2020

Press release Second quarter 2021

All expectations, guidance and targets regarding future performance and dividend payments should be read together with ‘Outlook, assumptions and cautionary statements’ on pages 68 and 69. If exchange rates were to hold at the closing rates on 30 June 2021 ($1.39/£1, €1.17/£1 and Yen 153/£1) for the rest of 2021, the

  Dividend, And dividends

EvaluatePharma World Preview 2019, Outlook to 2024

growing demand from emerging economies, reaching the report’s forecast of ... This can be compared to the forecast annual CAGR of +6.9% for 2019 through 2024 with expected sales to reach $1.18trn. The ... Novartis EvaluatePharma® World Preview 2019. EvaluatePharma ...

  Annual, Report, 2019, Novartis, Evaluatepharma, Novartis evaluatepharma

Novartis Annual Report 2019

Annual Report 2019. Annual Report 2019. I Chairman’s letter Novartis delivered strong performance in 2019. New ... consolidated financial statements responsive to Item 18 of this Annual Report on Form 20-F (Annual Report) are ... words or phrases in this Annual Report refer to Novartis AG and its consolidated affiliates. However, each Group ...

  Annual, Report, Annual report, 2019, Novartis, Annual report 2019, Novartis annual report 2019

Division of Enforcement 2020 Annual Report - SEC.gov

I am pleased to share the Division of Enforcement’s annual report for Fiscal Year 2020. And what a year it was. Like everyone, the challenges we faced – and continue to face – were unexpected and beyond imagination. In response to these extraordinary challenges, ... Novartis AG. In a settled action, the Commission found that local ...

  Annual, Report, Annual report, Novartis

2020 Annual Report

Agreements with Novartis in early 2021, we will channel more energy toward creating greater value in the eye care industry. Our financial performance in 2020 reflects strong commercial execution and the decisions we made to protect our associates and continue with our strategic investments. iv Alcon Annual Report 2020

  Annual, Report, Annual report, Novartis

ASEAN Pharma Report: Opportunities & Threats 2020 and …

Novartis’ biologics plants, with the companies investing $80mxi and $500mxii respectively. Singapore’s biomedical manufacturing output has increased subsequently by nearly 10% in the first half of 2019 compared to the corresponding half of 2018. This has further established its reputation as a prosperous biomedical manufacturing hubxiii.

  Report, 2019, Novartis

PFE - 12/31/2020 - 10K

2018 Financial Report Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 Form 10-K This Annual Report on Form 10-K for the fiscal year ended December 31, 2020 Proxy Statement Proxy Statement for the 2021 Annual Meeting of Shareholders, which will be filed no later than 120 days after

  Annual, Report, Annual report

2020 Impact Report - Coursera

2020 Impact Report 4 Welcome to Coursera’s first-ever impact report. Coursera was founded in 2012 with a mission of providing universal access to world-class learning. At no time in Coursera’s history has this mission been more relevant or urgent. The world is facing unprecedented economic disruption, and the need

  Report, Impact, Impact report